PATENT CLAIM ANALYSIS

Application Number: 15975462
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "303000"]

Abstract:
Provided are triazolopyridine compounds that are inhibitors of JAK kinase, such as JAK1, compositions containing these compounds and methods for treating diseases mediated by a JAK kinase. In particular, provided are compounds of formula (I), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where R 1a , R 1b , R 1c , R 2 , R 3 , R 4  and R 5  are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by a JAK kinase in a patient.

Claim (Index 4):
A method of preventing, treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient, comprising administering to the patient a therapeutically effective amount of a compound of  claim 1  or  claim 2 , or a pharmaceutically acceptable salt or stereoisomer thereof.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 93.0
- Lexical Diversity: 1.83582
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15499662', '14049458', '13471269', '13004808', '14720323']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7591664585995103
- 35 USC 102 Novelty (BERT): 0.5740618893199669
- Combined Prediction Score: 0.7406560016715559
- Mean Citation Score: 386.797376
- Max Citation Score: 452.7919
- Similarity Product: 406.9982983878016

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test